Autism Spectrum Disorder
Autism Spectrum Disorder

Autism Spectrum Disorder Comprehensive Study by Type (Applied Behavior Analysis, Discrete Trial Teaching, Pivotal Response Treatment), Indication (Insomnia, Epilepsy, Depression, Hyperactivity & Inattention, Others), Channel (Hospital Pharmacies, Retail Pharmacies, Others) Players and Region - Global Market Outlook to 2024

Autism Spectrum Disorder Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Sep 2019 Edition 249 Pages 223 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Autism Spectrum Disorder Market Overview:
Autism Spectrum Disorder (ASD) refers to the mental imbalance which is generally linked to the seizures, lack of sound sleep, and gastrointestinal (GI) distress. The heady lifestyle is the root cause of ASD's existence that is affecting a number of children as well as adults. Although many experts assert that there is no cure of Autism; following the line of treatments continually assures good outcomes. Specialists are increasingly developing breakthrough therapies and treatments using the technological advancements which are phenomenally close. Some of the key players profiled in the study are Pfizer Inc. (United States), GlaxoSmithKline plc (United Kingdom), Eli Lilly & Company (United States), Merck & CO Inc. (United States), Allergan (Ireland), Consern Pharma Pvt.Ltd. (India), Johnson & Johnson (United States) and Roche (Switzerland).

On the basis of geography, the market of Autism Spectrum Disorder has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Indication, the sub-segment i.e. Insomnia will boost the Autism Spectrum Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Channel, the sub-segment i.e. Hospital Pharmacies will boost the Autism Spectrum Disorder market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Prevalence of Mental Disorders like Autism due to Fast life and Various Prevailing Addictions
  • Rise in Demand for Sophisticated Therapy by Physicians and Patients

Market Trend
  • Technological Advancements in the Field of Medical Science

Restraints
  • Lack of Awareness About Autism Spectrum Disorder in Developing Regions
  • High Cost of Therapy
  • Lack of Medical Infrastructure

Opportunities
  • Collaboration & Tie ups of Leading Players

Challenges
  • Lack of Trained Professionals


In December 2018, Q BioMed Inc. (US), a biomedical acceleration and development company announced its partnership with SRI International (US), an independent, non-profit research centre that serves government and industry to help commercialize products to Develop Pediatric Developmental Nonverbal Disorder Therapy.

According to the CDC (Centers for Disease Control and Prevention), 1 in 68 children in the U.S is affected with an autism spectrum disorder, and each year around 50,000 children lose their basic education as they are affected with an autism spectrum disorder. Autism spectrum disorder is more shown by boys then that of girls, as per CDC itís about 4.5 more in boys than girls.

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Autism Spectrum Disorder market on the basis of product [Applied Behavior Analysis, Discrete Trial Teaching and Pivotal Response Treatment] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Autism Spectrum Disorder market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Autism Spectrum Disorder industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Otsuka and AstraZeneca.
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Autism Spectrum Disorder market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Applied Behavior Analysis
  • Discrete Trial Teaching
  • Pivotal Response Treatment
By Indication
  • Insomnia
  • Epilepsy
  • Depression
  • Hyperactivity & Inattention
  • Others

By Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Mental Disorders like Autism due to Fast life and Various Prevailing Addictions
      • 3.2.2. Rise in Demand for Sophisticated Therapy by Physicians and Patients
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Field of Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Autism Spectrum Disorder, by Type, Indication, Channel and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Autism Spectrum Disorder (Value)
      • 5.2.1. Global Autism Spectrum Disorder by: Type (Value)
        • 5.2.1.1. Applied Behavior Analysis
        • 5.2.1.2. Discrete Trial Teaching
        • 5.2.1.3. Pivotal Response Treatment
      • 5.2.2. Global Autism Spectrum Disorder by: Indication (Value)
        • 5.2.2.1. Insomnia
        • 5.2.2.2. Epilepsy
        • 5.2.2.3. Depression
        • 5.2.2.4. Hyperactivity & Inattention
        • 5.2.2.5. Others
      • 5.2.3. Global Autism Spectrum Disorder by: Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Others
      • 5.2.4. Global Autism Spectrum Disorder Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Autism Spectrum Disorder (Price)
      • 5.3.1. Global Autism Spectrum Disorder by: Type (Price)
  • 6. Autism Spectrum Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly & Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & CO Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Allergan (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Consern Pharma Pvt.Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Autism Spectrum Disorder Sale, by Type, Indication, Channel and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Autism Spectrum Disorder (Value)
      • 7.2.1. Global Autism Spectrum Disorder by: Type (Value)
        • 7.2.1.1. Applied Behavior Analysis
        • 7.2.1.2. Discrete Trial Teaching
        • 7.2.1.3. Pivotal Response Treatment
      • 7.2.2. Global Autism Spectrum Disorder by: Indication (Value)
        • 7.2.2.1. Insomnia
        • 7.2.2.2. Epilepsy
        • 7.2.2.3. Depression
        • 7.2.2.4. Hyperactivity & Inattention
        • 7.2.2.5. Others
      • 7.2.3. Global Autism Spectrum Disorder by: Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Others
      • 7.2.4. Global Autism Spectrum Disorder Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Autism Spectrum Disorder (Price)
      • 7.3.1. Global Autism Spectrum Disorder by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Autism Spectrum Disorder: by Type(USD Million)
  • Table 2. Autism Spectrum Disorder Applied Behavior Analysis , by Region USD Million (2013-2018)
  • Table 3. Autism Spectrum Disorder Discrete Trial Teaching , by Region USD Million (2013-2018)
  • Table 4. Autism Spectrum Disorder Pivotal Response Treatment , by Region USD Million (2013-2018)
  • Table 5. Autism Spectrum Disorder: by Indication(USD Million)
  • Table 6. Autism Spectrum Disorder Insomnia , by Region USD Million (2013-2018)
  • Table 7. Autism Spectrum Disorder Epilepsy , by Region USD Million (2013-2018)
  • Table 8. Autism Spectrum Disorder Depression , by Region USD Million (2013-2018)
  • Table 9. Autism Spectrum Disorder Hyperactivity & Inattention , by Region USD Million (2013-2018)
  • Table 10. Autism Spectrum Disorder Others , by Region USD Million (2013-2018)
  • Table 11. Autism Spectrum Disorder: by Channel(USD Million)
  • Table 12. Autism Spectrum Disorder Hospital Pharmacies , by Region USD Million (2013-2018)
  • Table 13. Autism Spectrum Disorder Retail Pharmacies , by Region USD Million (2013-2018)
  • Table 14. Autism Spectrum Disorder Others , by Region USD Million (2013-2018)
  • Table 15. South America Autism Spectrum Disorder, by Country USD Million (2013-2018)
  • Table 16. South America Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 17. South America Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 18. South America Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 19. Brazil Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 20. Brazil Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 21. Brazil Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 22. Argentina Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 23. Argentina Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 24. Argentina Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 25. Rest of South America Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 26. Rest of South America Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 27. Rest of South America Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 28. Asia Pacific Autism Spectrum Disorder, by Country USD Million (2013-2018)
  • Table 29. Asia Pacific Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 30. Asia Pacific Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 31. Asia Pacific Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 32. China Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 33. China Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 34. China Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 35. Japan Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 36. Japan Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 37. Japan Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 38. India Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 39. India Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 40. India Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 41. South Korea Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 42. South Korea Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 43. South Korea Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 44. Taiwan Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 45. Taiwan Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 46. Taiwan Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 47. Australia Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 48. Australia Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 49. Australia Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 53. Europe Autism Spectrum Disorder, by Country USD Million (2013-2018)
  • Table 54. Europe Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 55. Europe Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 56. Europe Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 57. Germany Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 58. Germany Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 59. Germany Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 60. France Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 61. France Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 62. France Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 63. Italy Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 64. Italy Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 65. Italy Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 66. United Kingdom Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 67. United Kingdom Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 68. United Kingdom Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 69. Netherlands Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 70. Netherlands Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 71. Netherlands Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 72. Rest of Europe Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 73. Rest of Europe Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 74. Rest of Europe Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 75. MEA Autism Spectrum Disorder, by Country USD Million (2013-2018)
  • Table 76. MEA Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 77. MEA Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 78. MEA Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 79. Middle East Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 80. Middle East Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 81. Middle East Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 82. Africa Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 83. Africa Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 84. Africa Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 85. North America Autism Spectrum Disorder, by Country USD Million (2013-2018)
  • Table 86. North America Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 87. North America Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 88. North America Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 89. United States Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 90. United States Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 91. United States Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 92. Canada Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 93. Canada Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 94. Canada Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 95. Mexico Autism Spectrum Disorder, by Type USD Million (2013-2018)
  • Table 96. Mexico Autism Spectrum Disorder, by Indication USD Million (2013-2018)
  • Table 97. Mexico Autism Spectrum Disorder, by Channel USD Million (2013-2018)
  • Table 98. Autism Spectrum Disorder: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Autism Spectrum Disorder: by Type(USD Million)
  • Table 108. Autism Spectrum Disorder Applied Behavior Analysis , by Region USD Million (2019-2024)
  • Table 109. Autism Spectrum Disorder Discrete Trial Teaching , by Region USD Million (2019-2024)
  • Table 110. Autism Spectrum Disorder Pivotal Response Treatment , by Region USD Million (2019-2024)
  • Table 111. Autism Spectrum Disorder: by Indication(USD Million)
  • Table 112. Autism Spectrum Disorder Insomnia , by Region USD Million (2019-2024)
  • Table 113. Autism Spectrum Disorder Epilepsy , by Region USD Million (2019-2024)
  • Table 114. Autism Spectrum Disorder Depression , by Region USD Million (2019-2024)
  • Table 115. Autism Spectrum Disorder Hyperactivity & Inattention , by Region USD Million (2019-2024)
  • Table 116. Autism Spectrum Disorder Others , by Region USD Million (2019-2024)
  • Table 117. Autism Spectrum Disorder: by Channel(USD Million)
  • Table 118. Autism Spectrum Disorder Hospital Pharmacies , by Region USD Million (2019-2024)
  • Table 119. Autism Spectrum Disorder Retail Pharmacies , by Region USD Million (2019-2024)
  • Table 120. Autism Spectrum Disorder Others , by Region USD Million (2019-2024)
  • Table 121. South America Autism Spectrum Disorder, by Country USD Million (2019-2024)
  • Table 122. South America Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 123. South America Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 124. South America Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 125. Brazil Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 126. Brazil Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 127. Brazil Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 128. Argentina Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 129. Argentina Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 130. Argentina Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 131. Rest of South America Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 132. Rest of South America Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 133. Rest of South America Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 134. Asia Pacific Autism Spectrum Disorder, by Country USD Million (2019-2024)
  • Table 135. Asia Pacific Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 136. Asia Pacific Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 137. Asia Pacific Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 138. China Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 139. China Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 140. China Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 141. Japan Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 142. Japan Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 143. Japan Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 144. India Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 145. India Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 146. India Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 147. South Korea Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 148. South Korea Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 149. South Korea Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 150. Taiwan Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 151. Taiwan Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 152. Taiwan Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 153. Australia Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 154. Australia Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 155. Australia Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 156. Rest of Asia-Pacific Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 157. Rest of Asia-Pacific Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 158. Rest of Asia-Pacific Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 159. Europe Autism Spectrum Disorder, by Country USD Million (2019-2024)
  • Table 160. Europe Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 161. Europe Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 162. Europe Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 163. Germany Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 164. Germany Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 165. Germany Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 166. France Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 167. France Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 168. France Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 169. Italy Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 170. Italy Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 171. Italy Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 172. United Kingdom Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 173. United Kingdom Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 174. United Kingdom Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 175. Netherlands Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 176. Netherlands Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 177. Netherlands Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 178. Rest of Europe Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 179. Rest of Europe Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 180. Rest of Europe Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 181. MEA Autism Spectrum Disorder, by Country USD Million (2019-2024)
  • Table 182. MEA Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 183. MEA Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 184. MEA Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 185. Middle East Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 186. Middle East Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 187. Middle East Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 188. Africa Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 189. Africa Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 190. Africa Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 191. North America Autism Spectrum Disorder, by Country USD Million (2019-2024)
  • Table 192. North America Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 193. North America Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 194. North America Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 195. United States Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 196. United States Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 197. United States Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 198. Canada Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 199. Canada Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 200. Canada Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 201. Mexico Autism Spectrum Disorder, by Type USD Million (2019-2024)
  • Table 202. Mexico Autism Spectrum Disorder, by Indication USD Million (2019-2024)
  • Table 203. Mexico Autism Spectrum Disorder, by Channel USD Million (2019-2024)
  • Table 204. Autism Spectrum Disorder: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Autism Spectrum Disorder: by Type USD Million (2013-2018)
  • Figure 5. Global Autism Spectrum Disorder: by Indication USD Million (2013-2018)
  • Figure 6. Global Autism Spectrum Disorder: by Channel USD Million (2013-2018)
  • Figure 7. South America Autism Spectrum Disorder Share (%), by Country
  • Figure 8. Asia Pacific Autism Spectrum Disorder Share (%), by Country
  • Figure 9. Europe Autism Spectrum Disorder Share (%), by Country
  • Figure 10. MEA Autism Spectrum Disorder Share (%), by Country
  • Figure 11. North America Autism Spectrum Disorder Share (%), by Country
  • Figure 12. Global Autism Spectrum Disorder: by Type USD/Units (2013-2018)
  • Figure 13. Global Autism Spectrum Disorder share by Players 2018 (%)
  • Figure 14. Global Autism Spectrum Disorder share by Players (Top 3) 2018(%)
  • Figure 15. Global Autism Spectrum Disorder share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2018
  • Figure 21. Eli Lilly & Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly & Company (United States) Revenue: by Geography 2018
  • Figure 23. Merck & CO Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & CO Inc. (United States) Revenue: by Geography 2018
  • Figure 25. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Allergan (Ireland) Revenue: by Geography 2018
  • Figure 27. Consern Pharma Pvt.Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 28. Consern Pharma Pvt.Ltd. (India) Revenue: by Geography 2018
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 31. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche (Switzerland) Revenue: by Geography 2018
  • Figure 33. Global Autism Spectrum Disorder: by Type USD Million (2019-2024)
  • Figure 34. Global Autism Spectrum Disorder: by Indication USD Million (2019-2024)
  • Figure 35. Global Autism Spectrum Disorder: by Channel USD Million (2019-2024)
  • Figure 36. South America Autism Spectrum Disorder Share (%), by Country
  • Figure 37. Asia Pacific Autism Spectrum Disorder Share (%), by Country
  • Figure 38. Europe Autism Spectrum Disorder Share (%), by Country
  • Figure 39. MEA Autism Spectrum Disorder Share (%), by Country
  • Figure 40. North America Autism Spectrum Disorder Share (%), by Country
  • Figure 41. Global Autism Spectrum Disorder: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Eli Lilly & Company (United States)
  • Merck & CO Inc. (United States)
  • Allergan (Ireland)
  • Consern Pharma Pvt.Ltd. (India)
  • Johnson & Johnson (United States)
  • Roche (Switzerland)
Additional players considered in the study are as follows:
Otsuka , AstraZeneca
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation